No Picture
Industry News

Lilly, Incyte’s baricitinib wins fast-track status for hard-to-treat lupus; Synthorx hammers out $150M+ IPO

? Rheumatoid arthritis drug Olumiant?? approved for a narrower-than-expected patient population earlier this year to the dismay of its manufacturer Eli?Lilly $LLY and Incyte $INCY which had blockbuster dreams for the drug?? may be worth its weight in g… […]

No Picture
Industry News

Lilly, Incyte’s baricitinib wins fast-track status for hard-to-treat lupus; Synthorx hammers out $150M+ IPO

? Rheumatoid arthritis drug Olumiant?? approved for a narrower-than-expected patient population earlier this year to the dismay of its manufacturer Eli?Lilly $LLY and Incyte $INCY which had blockbuster dreams for the drug?? may be worth its weight in g… […]

No Picture
Industry News

WuXi AppTec cruises toward a steady debut in Hong Kong stock exchange, ending flat on IPO price

Completing a grand plan for a dual listing in Shanghai and Hong Kong in the span of seven months, WuXi AppTec has debuted on the HKEX, ending the day at its original IPO price.
Net proceeds will register at $967 million (HK $7,553 million), the company… […]